Discussion
 
MaxSimil® Patented Lipid Absorption Enhancement Technology (PLATform)
The MaxSimil PLATform is a novel monoglyceride delivery system that enhances absorption of lipid-based and lipid-soluble nutraceutical and food ingredients. This technology has been applied to EPA/DHA Complex formulas in order to create a unique vehicle by which to deliver EPA and DHA.
Due to the fact that monoglyceride oils are intrinsically emulsifiers and are, by nature, in a readily absorbable form (Figure 1), they can bypass the body’s normal fat digestion process. These qualities make EPA/DHA Complex an excellent method for delivering omega-3 fatty acids, especially to individuals with digestive, pancreatic, or gall bladder challenges.
Studies show that MaxSimil fish oils (FO) have three times (300%) greater absorption of EPA and DHA compared to other leading fish oils.* [1–3]
Quality
EPA/DHA Complex formulas are made using proprietary MaxSimil compositions containing monoglyceride fish oil (FO) with no additional ingredients, carriers, or excipients. Each fish-gelatin softgel is enteric-coated, and every batch of fish oil is IFOS five-star certified to ensure the world’s highest standards for purity, potency, and freshness.
The fish oil is non-GMO, certified sustainable from Scandinavia, and antibiotic-free. Additionally, it is eco-friendly because the greater absorption of EPA and DHA ultimately means that fewer grams of fish oil need to be harvested to achieve the same benefit.
In Vitro and In Vivo Animal Studies
The ability of MaxSimil-enhanced EPA and DHA to positively influence growth inhibition and apoptosis has been demonstrated in colorectal, breast, lung, and prostate diseased cell models.
No toxicity was observed at either dose level. [1,2] This research demonstrated superior bioavailability and presumably better exposure of cells to DHA. Figure 2. Preclinical bioavailability study in rodents demonstrates superior peak concentration, saturation, and absorption of MaxSimil DHA FO versus its parent DHA FO.
Clinical Bioavailability Study:
A phase 1, double-blind, randomized, crossover, pharmacokinetic study was performed in 20 healthy adults aged between 19 and 71 years who were administered 6 g per day (containing 1800 mg EPA and 1200 mg DHA) of either EE FO or MaxSimil FO. [3] Parameters studied included plasma EPA and DHA concentrations (as a percent of total fatty acids). Compared to EE EPA + DHA, the results indicated that at peak concentration, MaxSimil EPA and DHA levels were three times higher. They also reached maximum concentration faster and maintained their plasma levels longer (Figure 3). The findings from the animal study were validated: MaxSimil FO showed three times greater instantaneous absorption than the EE form. Likewise, the AUC over 24 hours was more than three times higher (P<.0001) for MaxSimil EPA and DHA. Not only did this study confirm the bioavailability findings from the animal study, but it also demonstrated that after 24 hours, MaxSimil FO maintained 2–3 times higher blood levels of EPA and DHA compared to EE FO. This suggests that with daily dosing, circulating EPA and DHA levels can build up over time and remain elevated, leading to a steady increase in cellular exposure to EPA, DHA, and their metabolites. Based on the results of the bioavailability studies, individuals would get more EPA and DHA from MaxSimil FO than from EE FO on a gram-for-gram basis. Furthermore, as shown in animal studies, enhanced effects could be anticipated. Notably, all 20 adults who completed the study experienced improved omega-3 absorption when taking the MaxSimil-enhanced FO.*
Expanding Research:
In vitro and animal studies have demonstrated the positive effects of MaxSimil FO on airway immune responses, such as immunoglobulin E (IgE) levels and leukocyte activity. Additional findings include modulation of the expression of COX-2, NF-κB, cytokines like IL-6 and IL-8, MUC5AC, mucin, and calcium (Ca²⁺) hypersensitivity in lung tissues. [8–11] In another line of research, rats subjected to eight weeks of a high-fat, high-carbohydrate diet were either not supplemented or provided 3 g/day of MaxSimil DHA.
Directions:
Take one softgel daily, or as directed by your healthcare professional. Consult your healthcare practitioner prior to use. Individuals taking blood thinners or other medications should discuss potential interactions with their healthcare practitioner. Do not use if the tamper seal is damaged.
Storage:
Keep tightly closed in a cool, dry place out of reach of children.
Formulated to Exclude:
Wheat, gluten, corn, yeast, soy protein, dairy products, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, and artificial preservatives.
Clinical Applications:
» Positively Affects the Production of Arachidonic Acid-Derived Eicosanoids*
» Supports Cardiovascular Health*
» Supports Healthy Mental Functioning*
» Supports Healthy Glucose and Insulin Metabolism*
» By Supplying the Precursors EPA and DHA, Helps the Body Generate Specialized Proresolving Lipid Mediators, Such as Resolvins and Protectins
 
The EPA/DHA Complex features five-star certified monoglyceride fish oil that has a three times greater EPA+DHA absorption rate than an equivalent dose of other leading fish oils. Through the use of patented lipid absorption enhancement technology (PLATform), the fish oil is absorption-ready and can be directly assimilated in the intestinal tract for maximum benefit.
Subsequently set out to demonstrate efficacy in animal models after oral administration. In three separate animal models, MaxSimil EPA and DHA forms showed superior activity on diseased cell-line growth inhibition and cytokine production when compared to control, corn oil, krill oil, or the parent forms ethyl ester (EE) EPA and ethyl ester (EE) DHA. [4,7,8] These in vivo animal studies proved that orally supplemented MaxSimil EPA and DHA were well-absorbed and bioactive. Researchers postulated that the observed superior effects of MaxSimil EPA and DHA forms were the result of enhanced absorption, and they set out to prove this hypothesis.*
Preclinical Bioavailability Studies: The in vivo pharmacokinetic studies in rodents involved a comparison between MaxSimil DHA FO and its parent EE DHA FO and an analysis of blood concentrations of DHA over time. The doses used were equivalent to human doses of 3 g/day and 30 g/day; the latter was included primarily to investigate toxicity at high doses. Researchers found that MaxSimil DHA FO had a three times (3x) higher peak concentration (6% versus 2%, Figure 2), a 3x higher saturation potential at the high dose (10% versus 3%), and a 3x higher absorption rate (at a 3 g/day equivalent human dose) than its parent DHA FO.
References
Unpublished, internal data. Ingenutra.
Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof. US patent 8,198,324. June 12, 2012.
MaxSimil Patented Lipid Absorption Technology Clinical Study Report: MaxSimil® 3020 Omega-3. Sherbrooke (Québec), Canada: Ingenutra; 2015. [Unpublished, internal data]